DM Healthcare Investment

Asia Regenerative Medicine Ltd. Successfully Completes Pre-A+ Round, Raises 12.2M USD

June 30, 2023

SHENZHEN, China, June 30, 2023 -- Asia Regenerative Medicine Limited (also known as ARM) is pleased to announce that it successfully concluded its Pre-A+ round raise of 88M RMB (~12.2M USD). 

In order to extend the lives of patients with high quality, Asia Regenerative Medicine has developed artificial kidneys and artificial pancreas for the two major diseases of kidney disease and diabetes since its establishment in 2018, and has established a complete It has a tissue engineering device production base, stem cell differentiation platform, pharmacodynamic and toxicological model team and clinical transformation team, and has made phased progress.

Since its establishment 5 years ago, Asia Regenerative Medicine has also built a GMP-level bioartificial organ equipment and cell workshop. The products of artificial kidneys and pancreas are gradually converted into production. It plans to enter IND in batches in 2024, and some products have completed IIT. This round of financing will promote the company’s products. Prior to this round of financing, Asia Regenerative Medicine had received investment from a number of leading domestic investment institutions including Sequoia Seed Fund.

Congratulations to the ARM team, and we look forward to seeing what the team achieves moving forward.